The effect of bevacizumab treatment on reading ability in age related macular degeneration - Reading after bevacizumab treatment in AMD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-024001-12-FI

Enrollment

Registered

2010-12-02

Start date

2011-01-27

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age related macular degeneration of the eye, wet form MedDRA version: 12.1 Level: LLT Classification code 10064930 Term: Age-related macular degeneration

Interventions

Trade Name: AVASTIN 25MG/ML INF KONSENTR, LIUOSTA VARTEN Pharmaceutical Form: Solution for infusion INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients from the Department of Ophthalmology, Turku University Hospital, which have wet form of age related macular degeneration of the eye and are decided to be treated with intravitreal bevacizumab according to hospitals routine clinical guidelines. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: No other eye diseases

Design outcomes

Primary

Measure	Time frame
Main Objective: to document the effect of intravitreal bevacizumab treatment on reading ability and foveal and parafoveal vision in age related macular degeneration (wet form);Secondary Objective: to validate internationally comparable methods for measuring reading ability;Primary end point(s): Follow up visit 12 months after first intravitreal bevacizumab injection.	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026